Many GLP-1 patients prescribed for obesity or excess unhealthy weight have struggled to maintain coverage, pay increased costs for coverage, or find the money to buy their medicine without insurance help
A total of 226,060 patients with overweight or obesity, including 29% with type 2 diabetes, were included
Therefore, in peri- and post-menopausal patients, rapid or substantial weight loss while on semaglutide may plausibly unmask or intensify GSM symptoms via endocrine and tissue-level changesalthough the specific contribution of semaglutide vs weight loss per se is not established
That said, like any medication, they arent without risks
This typically involves measurement of IGF-1 levels and, where indicated, dynamic stimulation testing
According to a study by Sun et al., IL6 and IL8 secretion was elevated in erastin-treated retinal pigment epithelial cells as senescence-associated factors [16]